ArticleFrontiers in immunology2024

Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma.

Haibo Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.